AS and CR are members of the Scottish Government Chief Medical Officer's COVID-19 Advisory Group. AS is a member of the NERVTAG Risk Stratification Subgroup and an unfunded member of AstraZeneca's COVID-19 strategic consultancy group, the Thrombocytopenia Taskforce. CR is a member of the Scientific Pandemic Influenza Group on Modelling and the Medicines and Healthcare Products Regulatory Agency COVID-19 Vaccine Benefit and Risk Working Group. JLKM is a member of the COVID Scottish National Incident Management Team. CM reports research funding from the Medical Research Council, Health Data Research UK, National Institute for Health Research, and the Scottish Chief Science Office. All other authors declare no competing interests. EAVE II is funded by the Medical Research Council with the support of BREATHE, the health data research hub for respiratory health, which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. Additional support was provided through Public Health Scotland and the Scottish Government Director-General Health and Social Care. The research for this Correspondence is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation. UA and CM acknowledge funding from Health Data Research UK (Measuring and Understanding Multimorbidity using Routine Data in the UK—HDR-9006; CFC0110). The funding source had no involvement in data collection, study design, data analysis, interpretation of findings, or the decision to publish this Correspondence. We thank Dave Kelly (Albasoft, Inverness, UK) for support with making primary care data available, Iain Mclaughlin (Public Health Scotland, Glasgow, UK) for help with the identification of the unvaccinated cohort, and James Pickett (Health Data Research UK, London, UK), Wendy Inglis-Humphrey, Vicky Hammersley, Maria Georgiou, Laura Gonzalez Rienda (Usher Institute, University of Edinburgh, Edinburgh, UK), Morna Coote, Amanda Burridge, Amie Wilson, and Megan Gorman (Public Health Scotland, Glasgow, UK) for project management and administration support. We acknowledge the support of the EAVE II Patient Advisory Group for their help with interpretation of findings and suggestions for dissemination and engagement. SSH and EH contributed equally. AS and CR contributed equally.